

Docket No.: 068911-0018

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Babish et al.

Customer No.: 41552

Appl. No. : 09/919,506

Confirmation No.: 2768

Filed : July 31, 2001

Title : COMBINATIONS OF
SESQUITERPENE LACTONES
AND DITEPENE LACTONES OR
TRITERPENES FOR
SYNERGISTIC INHIBITION OF
CYCLOOXYGENASE-2

Grp./A.U. : 1654

Examiner: : Patricia A. Patten

CERTIFICATE OF MAILING BY EXPRESS MAIL(37 CFR § 1.10)

"Express Mail" Mailing Label Number EV 540266901 US

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September 2, 2004.

Jose R. Lopez, Jr.
Jose R. Lopez, Jr.

INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

09/09/2004 HDEKES1 00000004 502624 09919506

03 FC:1806 180.00 DA

Serial No.: 09/919,506

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

In accordance with 37 CFR 1.17(p), please charge the fee of \$180.00 to Deposit Account No. 500417.

Please charge any shortage in fees due in connection with the filing of this paper, including extension of time fees, to Deposit Account 502624 and please credit any excess fees to such deposit account.

Respectfully submitted,

MCDERMOTT WILL & EMERY LLP



Deborah L. Cadena

Registration No. 44,048

4370 La Jolla Village Drive, Suite 700
San Diego, CA 92122
858.535.9001 DLC:JRL
Facsimile: 858.597.1585
Date: September 2, 2004
SDO 16449-1.068911.0018

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

 ATTY. DOCKET NO.
068911-0018

 SERIAL NO.
09/919,506

 APPLICANT
BABISH et al.

 FILING DATE
July 31, 2001

 GROUP
1654

(PTO-1449)

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 2002/0077350	06-20-2002	Babish et al.	
	2.	US 2003/0008021	01-09-2003	Babish et al.	
	3.	US 2003/0096027	05-22-2003	Babish et al.	
	4.	US 2003/0108628	06-12-2003	Babish et al.	
	5.	US 6,629,835	10-07-2003	Babish et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes - Number - Kind Codes (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation	
	6.	01/24053	02-07-2002	WO		Yes	No
	7.	02/19617	01-03-2003	WO			

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	8.	HWANG et al., "Inhibition of the Expression of Inducible Cyclooxygenase and Proinflammatory Cytokines by Sesquiterpene Lactones in Macrophages Correlates with the Inhibition of MAP Kinases," Biochemical and Biophysical Research Communications 226, 810-818 (1996), Article 1433.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.